U.S. Pharmaceuticals & Biotech Leverage Leaders

Vertex Pharmaceuticals

Market Cap: US$114.6b

Operates as a biotechnology company in the United States, Europe, and internationally.

Summit Therapeutics

Market Cap: US$10.7b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Ligand Pharmaceuticals

Market Cap: US$5.5b

A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.

Veracyte

Market Cap: US$4.3b

Operates as a diagnostics company in the United States and internationally.

BioMarin Pharmaceutical

Market Cap: US$10.6b

A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

West Pharmaceutical Services

Market Cap: US$23.2b

Designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Relay Therapeutics

Market Cap: US$3.5b

Operates as a clinical-stage precision medicines company.

Pharvaris

Market Cap: US$2.3b

A late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.

Kymera Therapeutics

Market Cap: US$7.4b

A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

Aurinia Pharmaceuticals

Market Cap: US$2.1b

A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.

Regencell Bioscience Holdings

Market Cap: US$6.0b

Operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.

Edgewise Therapeutics

Market Cap: US$4.0b

A biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.

Alumis

Market Cap: US$3.0b

A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

Natera

Market Cap: US$33.1b

A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.

10x Genomics

Market Cap: US$4.4b

Develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.

Immunovant

Market Cap: US$7.3b

A clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.

BioNTech

Market Cap: US$23.0b

Engages in the development and commercialization of immunotherapies in Germany.

Centessa Pharmaceuticals

Market Cap: US$6.2b

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.

Kodiak Sciences

Market Cap: US$2.3b

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Medpace Holdings

Market Cap: US$13.1b

Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.

Revolution Medicines

Market Cap: US$34.7b

A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

Danaher

Market Cap: US$125.4b

Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

Beam Therapeutics

Market Cap: US$3.4b

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

Parabilis Medicines

Market Cap: US$3.3b

Operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.

Disc Medicine

Market Cap: US$2.7b

A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.

Xenon Pharmaceuticals

Market Cap: US$5.1b

A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.

Belite Bio

Market Cap: US$5.7b

A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.

NewAmsterdam Pharma

Market Cap: US$3.5b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

Bio-Rad Laboratories

Market Cap: US$7.7b

Develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.

Denali Therapeutics

Market Cap: US$3.7b

A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.

Praxis Precision Medicines

Market Cap: US$7.9b

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

BeOne Medicines

Market Cap: US$30.0b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

Repligen

Market Cap: US$7.4b

A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Definium Therapeutics

Market Cap: US$2.7b

A clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.

Mineralys Therapeutics

Market Cap: US$2.0b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

Cogent Biosciences

Market Cap: US$5.9b

A clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.